Medicare Part B: Expenditures for New Drugs Concentrated among a Few Drugs, and Most Were Costly for Beneficiaries

Home > Diane Publishing Books >

Our Price: $20.00

By James Cosgrove (au)
Year: 2015
Pages: 39
Binding Paperback
ISBN 978-1-4578-7141-2

Product Code: 1457871416

Description

Some of the drugs approved in recent years by the Department of Health and Human Servicesäó» (HHSäó») Food and Drug Administration (FDA) have been associated with high spending. This report provides information on trends in the costs of newly approved drugs in the Medicare Part B program and the potential implications of these costs for the Medicare program and its beneficiaries. The report (1) describes the drugs newly approved by FDA and paid for by Medicare Part B and compares them to drugs newly approved and not paid for by Part B; and (2) examines, for new Part B drugs, patterns of Medicare expenditures, including overall Part B expenditures and expenditures per beneficiary, and utilization. Tables. This is a print on demand report.

Share your knowledge of this product with other customers... Be the first to write a review